**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Editorial

- 303** Hydroxychloroquine and lupus flare: a good drug, but we need to do better
M K Crow, K A Kirou

Viewpoint

- 306** Time to reconsider what Global Burden of Disease studies really tell us about low back pain
C Maher, G Ferreira

Criteria

- 309** 2022 American College of Rheumatology/ European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis
P C Grayson, C Ponte, R Suppiah, J C Robson, A Craven, A Judge, S Khalid, A Hutchings, R A Luqmani, R A Watts, P A Merkel

- 315** 2022 American College of Rheumatology/ European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis
J C Robson, P C Grayson, C Ponte, R Suppiah, A Craven, A Judge, S Khalid, A Hutchings, R A Watts, P A Merkel, R A Luqmani

- 321** 2022 American College of Rheumatology/ European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
R Suppiah, J C Robson, P C Grayson, C Ponte, A Craven, S Khalid, A Judge, A Hutchings, P A Merkel, R A Luqmani, R A Watts

Rheumatoid arthritis

- 327** Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study
A Balsa, M J García de Yébenes, L Carmona, ADHIERA Study Group

- 335** Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
P C Taylor, T Takeuchi, G R Burmester, P Durez, J S Smolen, W Deberdt, M Issa, J R Terres, N Bello, K L Winthrop

- 344** Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment
K Holten, N Paulshus Sundlisater, S Lillegraven, J Sexton, L B Nordberg, E Moholt, H B Hammer, T Uhlig, T K Kvien, E A Haavardsholm, A-B Aga

Psoriatic arthritis

- 351** Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial
A Östör, F Van den Bosch, K Papp, C Asnal, R Blanco, J Aelion, G Alperovich, W Lu, Z Wang, A M Soliman, A Eldred, L Barcomb, A Kivitz

- 359** Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
L C Coates, L Gossec, E Theander, P Bergmans, M Neuhold, C S Karyekar, M Shawi, W Noël, G Schett, I B McInnes

Systemic lupus erythematosus

- 370** Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
C C Almeida-Brasil, J G Hanly, M Urowitz, A E Clarke, G Ruiz-Irastorza, C Gordon, R Ramsey-Goldman, M Petri, E M Ginzler, D J Wallace, S-C Bae, J Romero-Diaz, M A Dooley, C Peschken, D Isenberg, A Rahman, S Manzi, S Jacobsen, S Lim, R F van Vollenhoven, O Nived, A Jönsen, D L Kamen, C Aranow, J Sanchez-Guerrero, D D Gladman, P R Fortin, G S Alarcón, J T Merrill, K Kalunian, M Ramos-Casals, K Steinsson, A Zoma, A Askanase, M A Khamashta, I N Bruce, M Inanc, M Abrahamowicz, S Bernatsky

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

C O P E

Member since 2008


This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it


Autoimmunity


- 379** Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood
 *Y Wang, X Xie, C Zhang, M Su, S Gao, J Wang, C Lu, Q Lin, J Lin, M Matucci-Cerinic, D E Furst, G Zhang*

Behçet's disease

- 386** A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome
 *G Emmi, G Bagni, E Lastraioli, F Di Patti, A Bettiol, C Fiorillo, M Becatti, E Silvestri, M L Urban, L Emmi, D Prisco, A Arcangeli*

Treatment

- 398** Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
 *I E Christensen, S Lillegraven, P Mielnik, G Bakland, L Loli, J Sexton, T Uhlig, T K Kvien, S A Provan*

- 402** Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy
 *N Ghalandari, E Kemper, I (Hubertina) Crijns, G Wolbink, T Rispens, H TW Smeele, R JEM Dolhain*

- 406** Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles
VE Saper, M J Ombrello, A H Tremoulet, G Montero-Martin, S Prahalad, S Canina, C Shimizu, G Deutsch, S Y Tan, E F Remmers, D Monos, T Hahn, O K Phadke, E Cassidy, I Ferguson, V Mallajosyula, J Xu, J S Rosa Duque, G T Chua, D Ghosh, A M Szymanski, D Rubin, J C Burns, L Tian, M A Fernandez-Vina, E D Mellins, J A Hollenbach, Drug Hypersensitivity Consortium, INCHARGE Consortium

Epidemiology


- 416** Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis
E Simader, S Tobudic, P Mandl, H Haslacher, T Perkmann, T Nothnagl, J Sautner, H Radner, F Winkler, H Burgmann, D Mrak, D Aletaha, S Winkler, S Blüml
- 422** Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
F P B Kroon, A Najm, A Alunno, J W Schoones, R B M Landewé, P M Machado, V Navarro-Compán


- 433** Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
H Bower, T Frisell, D Di Giuseppe, B Delcoigne, J Askeling

Letters

- 440** Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases
F Ursini, P Ruscitti, V Raimondo, R De Angelis, F Cacciapaglia, E Pigatto, D Olivo, I Di Cola, F Galluccio, F Francioso, R Foti, A Tavoni, S D'Angelo, C Campochiaro, F Motta, M De Santis, S Bilia, C Bruno, G De Luca, M Visentini, J Ciaffi, L Mancarella, V Brusi, M D'Onghia, G Cuomo, E Fusaro, L Dagna, S Guiducci, R Meliconi, F Iannone, A Iagnocco, R Giacomelli, C Ferri

- 441** Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2
M Visentini, L Gragnani, S A Santini, T Urraro, A Villa, M Monti, A Palladino, L Petraccia, F La Gualana, S Lorini, S Marri, F Madia, L Stefanini, S Basili, M Fiorilli, C Ferri, A L Zignego, M Casato

- 443** Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines
 *Y Fan, Y Geng, Y Wang, X Deng, G Li, J Zhao, L Ji, X Zhang, Z Song, H Zhang, X Sun, D Gao, W Xie, H Huang, Y Hao, Z Zhang*

- 445** Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA
 *K Martinsson, K Dürholz, G Schett, M M Zaiss, A Kastbom*

- 447** When extended genetics rescues diagnosis: a patient with CANDLE-like phenotype and de novo mutation in the *SAMD9L* gene
A Remy, C Borocco, G Sarrahay, G Boursier, S Fraïtag, B Catteau, H Reumaux, I Koné-Paut

- 448** Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behçet's syndrome?
S S Taflan, S N Esatoglu, Y Ozguler, B Yurttas, M Melikoglu, G Hatemi

Electronic pages

- e36** Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of *Gardnerella*?
D Liu, F Zhang, H Cao, X Wang

- e37** Response to: 'Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of *Gardnerella*?' by Liu *et al*
T Kishikawa, Y Maeda, T Nii, Y Okada
- e38** Questions on 'Sequencing of the MHC region defines *HLA-DQA1* as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo *et al*
C Regueiro, A Gonzalez
- e39** Response to: 'Questions on 'Sequencing of the MHC region defines *HLA-DQA1* as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo *et al*' by Regueiro and Gonzalez
J Guo, T Zhang, X Li, H Cao, Z Li
- e40** Reactive arthritis, a missing link: comment on the recent article from Sepriano *et al*
H Zeidler, A P Hudson
- e41** Response to: 'Reactive arthritis, a missing link: comment on the recent article from Sepriano *et al*' by Zeidler and Hudson
A Sepriano, S Ramiro, D van der Heijde, R B M Landewé
- e42** Secukinumab efficacy in patients with PsA is not dependent on patients' body mass index
I Pantano, D Iacono, E G Favalli, G Scalise, L Costa, F Caso, G Guggino, R Scarpa, F Ciccia
- e43** Prevalence of comorbidities and risk factors in spondyloarthritis: results of a cross-sectional study
Y Lai, Y Zhang, S Mo, J Ma, T Ni, Z Lei, J Xia, C Xu
- e44** Glucocorticoid withdrawal in lupus – to do or not to do?
N Acharya
- e45** Response to: 'Glucocorticoid withdrawal in lupus: to do or not to do?' by Acharya
A Mathian, M Pha, Z Amoura
- e46** Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial"
M R Mousavi, E Taherifard
- e47** Response to: 'Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial"' by Mousavi and Taherifard
A Mathian, M Pha, Z Amoura
- e48** Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies
H Yang, W Li, X Tian, G Wang, X Shu, Q Peng, X Lu
- e49** Response to: 'Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies' by Yang *et al*
L Spielmann, B Nespola, A Meyer
- e50** Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis
M Yamamoto, N Yoshikawa, H Tanaka
- e51** MRI and ultrasonography are useful tools for a non-invasive diagnosis of IgG4-related disease
A Lecler, T Sené
- e52** Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy
G Martin de Fremont, R Belkhir, J Henry, A L Voisin, O Lambotte, F L Besson, X Mariette, G Nocturne